In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th.
Amgen Inc., launched on October 31, 1986, is a biotechnology company. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company's stock worth $104,000 after purchasing an additional 4 shares during the last quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock.
Pacad Investment Ltd increased Tjx Cos Inc New (NYSE:TJX) stake by 9,700 shares to 28,500 valued at $2.06 million in 2017Q2. Alethea Capital Management Llc owns 248,150 shares or 1.61% of their U.S. portfolio. Legal & General Group Plc grew its holdings in shares of Amgen by 2.5% in the second quarter. The company's stock had a trading volume of 1,927,300 shares, compared to its average volume of 3,255,177. Jackson Grant Investment Advisers Inc. raised its holdings in Amgen by 0.6% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company's stock valued at $100,000 after purchasing an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC raised its holdings in Amgen by 19.0% during the 1st quarter. Integrated Wealth Management now owns 930 shares of the medical research company's stock valued at $141,000 after buying an additional 3 shares during the last quarter. The SI to Amgen Incorporated's float is 1.2%. Shares for $451,164 were sold by Patton Cynthia M. Company insiders own 0.19% of the company's stock. "(AMGN)" was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. (NASDAQ:AMGN) earned "Market Perform" rating by BMO Capital Markets on Wednesday, July 26. Cann restated a buy rating on shares of Amgen in a report on Monday, August 28th. Argus boosted their price objective on shares of Amgen from $180.00 to $195.00 and gave the company a "buy" rating in a report on Thursday, July 27th. Jefferies Group LLC reiterated a "buy" rating and set a $195.00 target price on shares of Amgen in a report on Monday, July 17th. Thirteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company.
Greystone Managed Investments Inc increased Canadian Natl Ry Co (CNI) stake by 2.63% reported in 2017Q2 SEC filing. Renaissance Technologies LLC lifted its position in shares of Amgen by 40.9% in the second quarter. Boston & invested 0.11% of its portfolio in Amgen, Inc. The stock declined 0.59% or $1.02 reaching $171.33 per share. 852,101 shares of the company traded hands, compared to its average volume of 3,246,733.
The company has a current ratio of 6.1 gauging towards its ability in paying short-term and long-term obligations. The firm has a market cap of $125,210.00, a P/E ratio of 13.80, a P/E/G ratio of 2.51 and a beta of 1.37. Amgen has a one year low of $138.83 and a one year high of $191.10. DiaMedica Therapeutics Inc (CVE:DMA) has 0.00% since November 12, 2016 and is.
TJX Companies sees shares drop as it announces flat store sales
ZWJ Investment Counsel Inc. bought a new position in shares of TJX Companies, Inc. (The) in the second quarter valued at $141,000. Moreover, Clearline Capital Lp has 1.79% invested in the company for 490,365 shares. (The) by 10.1% in the second quarter.
Among 22 analysts covering Amgen Inc. After $0.93 actual EPS reported by Morgan Stanley for the previous quarter, Wall Street now forecasts -16.13% negative EPS growth.
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. The firm's quarterly revenue was down.7% on a year-over-year basis.
Amgen declared that its Board of Directors has initiated a share repurchase plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Shareholders of record on Friday, November 17th will be given a $1.15 dividend. The ex-dividend date is Thursday, November 16th. This represents a $4.60 annualized dividend and a yield of 2.67%. With the existing current ratio, Amgen Inc.is more than equipped to confront its liabilities with its assets. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the firm's stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here.
Fastenal Company (NASDAQ:FAST) gained 0.11% with the closing price of $47.59. The stock of Amgen, Inc. The Company discovers, develops, manufactures and delivers various human therapeutics.
- Film stars, friends and family remember Paddington Bear author Michael Bond
- More and more stores are staying closed on Thanksgiving and Black Friday
- Israel issues strong warning against Hamas and Islamic Jihad
- Fidelity National Financial, Inc. (NYSE:FNF)
- The Geron Corp. (GERN) Issues Earnings Results, Beats Estimates By $0.04 EPS
- Kamal Haasan, Rajinikanth win NTR Award
- Louisville City FC wins USL Cup title
- Gopro Inc Cl A Cmn (GPRO) Valuation Review
- Phishing, keylogger : Google montre que les méthodes classiques de piratage restent efficaces
- Female Dem says at least two current members engaged in sexual harassment